Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib PK and Safety in Chinese Subjects with Solid Tumours
NCT02939846Phase 1Withdrawn
- Sponsor
- GSK
- Start
- May 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of trametinib in solid tumor, sponsored by GSK. Primary endpoints: Maximum Plasma Concentration at Day 22, Time to Maximum Plasma Concentration at Day 22 and 5 more. Planned start May 2017; status: withdrawn.
02
Drugs
trametinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02939846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939846.